Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

DeAndre Hopkins isn't ready to call it a career just yet. The veteran Chiefs wide receiver took to social media on Tuesday to address apparent whispers of his 12-year career coming to an end.

The Philadelphia Eagles to have Super Bowl LIX parade on February 14th. "GMFB" debates what does Super Bowl LIX loss do for ...

增资完成后，曲水奥城的股权结构中，王中锋持有31.5%的股权，杨瑞娜持有6.35%的股权，而西藏惠儒则持有62.15%的股权。增资前，王中锋和杨瑞娜夫妇通过曲水奥城持有濮阳惠成1.03亿股股份，占总股本的34.78%。增资后，西藏惠儒将间接控制濮阳惠成34.78%的股份，合计控制股份的比例为35.27%，剔除回购专户股份后，实际控制权比例为35.74%。此次股权结构调整并未导致控股股东和实际控制人 ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

新京报讯 2月11日，百奥泰发布公告，公司与Intas Pharmaceuticals Ltd.（以下简称“Intas”）签署授权许可与商业化协议，将公司的BAT2506（戈利木单抗）注射液在美国市场的独占的产品商业化权益有偿许可给Intas（以下简称“协议”或“本协议”）。百奥泰将负责研发、生产及商业化供应，Intas将通过其美国子公司Accord ...

2024年10月，广西中医药大学附属瑞康医院(广西壮族自治区中西医结合医院)在Journal of ...